Publication:
XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.

Simple item page
dc.contributor.authorUYGUN, K
dc.contributor.authorBILICI, A
dc.contributor.authorKAYA, S
dc.contributor.authorOven, Ustaalioglu
dc.contributor.authorYILDIZ, R
dc.contributor.authorTEMIZ, S
dc.contributor.authorSeker, MESUT
dc.contributor.authorAKSU, G
dc.contributor.authorCABUK, D
dc.contributor.authorGUMUS, M
dc.contributor.institutionauthorŞEKER, MESUT
dc.date.accessioned2020-10-29T23:47:47Z
dc.date.available2020-10-29T23:47:47Z
dc.date.issued2013-01-01T00:00:00Z
dc.identifier.citationUYGUN K., BILICI A., KAYA S., Oven U., YILDIZ R., TEMIZ S., Seker M., AKSU G., CABUK D., GUMUS M., -XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.-, Asian Pacific journal of cancer prevention : APJCP, cilt.14, ss.2283-8, 2013
dc.identifier.doi10.7314/apjcp.2013.14.4.2283
dc.identifier.scopus84880253316
dc.identifier.urihttp://hdl.handle.net/20.500.12645/26995
dc.identifier.wosWOS:000322198700025
dc.titleXELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
dc.typeArticle
dspace.entity.typePublication
local.avesis.iddb00e954-05b3-444f-8518-bd7bb8f53974
local.indexed.atWOS
local.indexed.atScopus
local.publication.goal03 - Sağlık ve Kaliteli Yaşam
local.publication.isinternational1
relation.isAuthorOfPublication8a03684e-e421-4a9f-9069-168fc121a5d4
relation.isAuthorOfPublication.latestForDiscovery8a03684e-e421-4a9f-9069-168fc121a5d4
relation.isGoalOfPublication9c198c48-b603-4e2f-8366-04edcfc1224c
relation.isGoalOfPublication.latestForDiscovery9c198c48-b603-4e2f-8366-04edcfc1224c

Files

Collections

Diğer Yayınlar